NCT00167102View on ClinicalTrials.gov

Alefacept in Patients With Severe Scalp Alopecia Areata

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Alopecia Areata
Interventions
DRUG

Alefacept

Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
collaborator

National Alopecia Areata Foundation

OTHER

lead

University of Minnesota

OTHER

NCT00167102 - Alefacept in Patients With Severe Scalp Alopecia Areata | Biotech Hunter | Biotech Hunter